TY - JOUR
T1 - Association Between DPP-4 Inhibitors and Events of Colorectal and Liver Cancers in Patients With Diabetes Receiving Second-Line Agents
T2 - A Nested Case-Control Study
AU - Chou, Chu Lin
AU - Juan, Shu Hui
AU - Li, Ching Hao
AU - Chen, Hsi Hsien
AU - Kao, Chih Chin
AU - Chen, Li Ying
AU - Chien, Li Nien
AU - Fang, Te Chao
N1 - Funding Information:
The study was financially sponsored by Taipei Medical University Hospital, Taipei Medical University, Taiwan (107TMU-TMUH-03 and 110TMU-TMUH-17). The funder had no role in study design, data collection and analysis, publication decision, and manuscript preparation.
Funding Information:
We thank the Bureau of Health Promotion, Department of Health, and National Health Research Institutes of Taiwan for providing access to the NHIRD, TCR, and NDR. The interpretations and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or National Health Research Institutes. This study was presented at the 2018 Annual Meeting of the Taiwan Society of Nephrology (Taoyuan, Taiwan, December 8–9, 2018). We thank Wallace Academic Editing for English editing of this manuscript. We acknowledge the support of the Health Data Analytics and Statistics Center, Office of Data Science, Taipei Medical University, Taiwan.
Publisher Copyright:
Copyright © 2022 Chou, Juan, Li, Chen, Kao, Chen, Chien and Fang.
PY - 2022/5/6
Y1 - 2022/5/6
N2 - Objective: Plasma dipeptidyl peptidase-4 (DPP4) levels were significantly lower in patients with colorectal and liver cancers, and animal studies also showed DPP4 inhibitors (DPP4is) have procarcinogenic effects in colorectal cancer. Until now, whether DPP4is therapy affects the progression of liver cancer and colorectal cancer in patients with T2DM has not been well investigated. We investigated the association between cumulative defined daily dose (cDDD) of DPP4is exposure and risks of liver and colorectal cancers in patients with type 2 diabetes. Materials and Methods: We identified 268,520 patients with diabetes receiving DPP4is as second-line agents between March 1, 2009, and December 31, 2013, from Taiwan’s National Health Insurance Research Database, Taiwan Cancer Registry, and National Death Registry of Taiwan. The amount of DPP4is were divided into three groups (low, medium, and high) based on the interquartile range of the cDDD of the DPP4is. Results: The data showed that the low cDDD of DPP-4is was associated with a reducing risk of colorectal cancer [adjusted odds ratio (OR), 0.49; 95% CI, 0.32–0.75; P=0.001]. However, the high cDDD of DPP-4is was associated with an increasing risk of colorectal cancer (adjusted OR, 1.86; 95% CI, 1.32–2.61; P<0.001). No association between DPP4is use and liver cancer risk was observed. Conclusions: This nested case study revealed a J-shaped association between the cDDD of DPP-4is and colorectal cancer risk, but not liver cancer risk. Therefore, the effects of long-term DPP4is use on colorectal cancer risk warrant further study.
AB - Objective: Plasma dipeptidyl peptidase-4 (DPP4) levels were significantly lower in patients with colorectal and liver cancers, and animal studies also showed DPP4 inhibitors (DPP4is) have procarcinogenic effects in colorectal cancer. Until now, whether DPP4is therapy affects the progression of liver cancer and colorectal cancer in patients with T2DM has not been well investigated. We investigated the association between cumulative defined daily dose (cDDD) of DPP4is exposure and risks of liver and colorectal cancers in patients with type 2 diabetes. Materials and Methods: We identified 268,520 patients with diabetes receiving DPP4is as second-line agents between March 1, 2009, and December 31, 2013, from Taiwan’s National Health Insurance Research Database, Taiwan Cancer Registry, and National Death Registry of Taiwan. The amount of DPP4is were divided into three groups (low, medium, and high) based on the interquartile range of the cDDD of the DPP4is. Results: The data showed that the low cDDD of DPP-4is was associated with a reducing risk of colorectal cancer [adjusted odds ratio (OR), 0.49; 95% CI, 0.32–0.75; P=0.001]. However, the high cDDD of DPP-4is was associated with an increasing risk of colorectal cancer (adjusted OR, 1.86; 95% CI, 1.32–2.61; P<0.001). No association between DPP4is use and liver cancer risk was observed. Conclusions: This nested case study revealed a J-shaped association between the cDDD of DPP-4is and colorectal cancer risk, but not liver cancer risk. Therefore, the effects of long-term DPP4is use on colorectal cancer risk warrant further study.
KW - colorectal cancer
KW - DPP-4 inhibitors
KW - liver cancer
KW - second-line agents
KW - type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85130619087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130619087&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.840142
DO - 10.3389/fonc.2022.840142
M3 - Article
AN - SCOPUS:85130619087
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 840142
ER -
